Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite pathways. Atovaquone inhibits the mitochondrial electron transport chain, disrupting energy production, while proguanil is converted to cycloguanil, which blocks dihydrofolate reductase, impairing folate synthesis. Together they cause rapid parasite death.

The dosing regimen for Malarone is determined by the prescribing clinician based on the indication, patient weight, age, and renal or hepatic function. Healthcare providers follow approved guidelines to select the appropriate tablet strength and schedule.

Safety data for atovaquone/proguanil during pregnancy and lactation are limited. Prescribers should weigh potential benefits against unknown risks and consider alternative therapies when possible. Women who are pregnant or nursing should discuss options with their healthcare professional.

To place an order, submit an enquiry on the Malarone product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone offers a convenient once‑daily oral regimen and combines two mechanisms of action, which can reduce the risk of resistance compared with single‑agent therapies such as chloroquine or mefloquine. However, choice of antimalarial depends on regional resistance patterns, patient tolerance and specific clinical circumstances.

Malarone tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain stability throughout the shelf life.

Malarone is taken orally with food or a milky drink to improve absorption. For prophylaxis, tablets are usually started 1–2 days before entering a malaria‑risk area, continued daily during exposure, and taken for 7 days after leaving the area. Treatment regimens follow the prescriber’s instructions.

Serious adverse events, though rare, include severe skin reactions such as Stevens‑Johnson syndrome, liver injury, hemolytic anemia in patients with G6PD deficiency, and anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, dark urine, or signs of an allergic reaction.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in those with G6PD deficiency when risk of hemolysis is a concern.